The funds will be mainly used to develop lead program Levodopa Cyclops™ for US and EEA marketing, of which early clinical studies already demonstrate...
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (...
Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) announced the launch of Mozarc Medical—an independent new company committed to reshap...
Ideal for the transportation of life-saving pharmaceutical, biotech and life-science products, Tower’s robust, reliable, reusable solutions are a wel...
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned su...
On 23 January 2023, the acceptance period during which DSM Shareholders can tender their DSM Ordinary Shares into the Exchange Offer was extended as not al...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the rol...
Having Dr. Adolfo Renzi at the prestigious Napoli hospital Ospedale Buon Consiglio Fatebenefratelli use RefluxStop and have such a posi...
Orion is building a unique pharmaceutical research ecosystem in Finland – using data and artificial intelligence to shorten the development time of n...
The EIC investment was made through its Accelerator Fund, designed to support small and medium enterprises (SMEs), in particular start-ups and spin-out com...
Artificial intelligence continues to expand rapidly and a new computer vision algorithm is now available to Moscow radiologists in city hospitals. It analy...
Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- ...
© 2024 Biopharma Boardroom. All Rights Reserved.
